B. Braun's Stimuplex Nerve Block Devices Gain Medicare Payment Approval Under NOPAIN Act

B. Braun's Nerve Block Devices and Medicare's NOPAIN Act

In an important development for pain management in surgical settings, B. Braun Medical Inc. has announced that its Stimuplex® Single-Shot Nerve Block Needles have received approval from the Centers for Medicare and Medicaid Services (CMS) for separate payment. This approval falls under the new Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act, effective from April 30, 2026. This act focuses on supporting non-opioid pain relief options in healthcare.

The NOPAIN Act was enacted to provide temporary separate payments for certain non-opioid drugs, biologics, or medical devices used primarily for pain relief post-surgery in outpatient settings. This initiative seeks to reduce reliance on opioid medications and improve patient outcomes by minimizing potential dependency issues. Currently, the act is scheduled to expire on December 31, 2027, unless Congress decides to renew it.

Kristin Brown, Director of Pain Control Marketing at B. Braun Medical Inc., emphasized the significance of this approval, stating, "The inclusion of these B. Braun peripheral nerve block devices under the NOPAIN Act reflects the essential role of innovative technologies in supporting opioid-sparing pain management strategies."

The approved devices utilize single-injection techniques that are invaluable in regional anesthesia procedures. Their effectiveness enhances the possibilities for multimodal pain management approaches, prioritizing patient health and safety.

As the leader in regional anesthesia in the U.S. market, B. Braun remains committed to advancing clinician education and evidence-based practices in pain management. The company believes that by providing safer alternatives to opioids, they can significantly contribute to better patient experiences and satisfaction in healthcare facilities.

For more details regarding the NOPAIN Act and B. Braun's comprehensive portfolio addressing regional anesthesia, healthcare providers can visit B. Braun’s official website.

About B. Braun Medical Inc.

Headquartered in Bethlehem, Pennsylvania, B. Braun is a leader in innovations related to smart infusion therapy and effective pharmacy products. Their commitment extends beyond just providing medical supplies; they focus on enhancing patient care and provider safety through sustainable health solutions. The B. Braun Group employs over 64,000 professionals across 64 countries, continually working to improve patient satisfaction and health outcomes.

The B. Braun philosophy, "Sharing Expertise®," drives their mission to collaborate with healthcare professionals and stakeholders to solve pressing issues in healthcare while actively lowering costs. B. Braun’s dedication to advancing healthcare technology aligns with ongoing efforts to improve chronic pain management and multi-faceted approaches to pain relief.

Navigating reimbursement in healthcare can be complex, and it's important for healthcare providers to understand the nuances around coding and payment policies. B. Braun advises that providers should consult relevant parties such as Medicare contractors, reimbursement specialists, or legal counsel to ensure compliance with all codes and regulations related to the use of their devices.

Final Thoughts

The approval of B. Braun's Stimuplex® devices is a significant step towards enhancing non-opioid pain management solutions in surgical settings, fostering a shift away from opioid reliance and paving the way for safer patient care practices. This move not only underscores B. Braun's commitment to innovation in pain management but also highlights the collaborative efforts necessary between healthcare stakeholders to advance patient-centric care.